Papers/PMID:38755142
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.
Nutrition & diabetes2024The record
5 findings · 1 compound · 5 endpoints · 1 null
What it reported
How to read these marksWhat moved
4 findings
taurine — decreases diastolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Quoted verbatim from Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Pooled 25 RCTs (1024 participants) of taurine supplementation, 0.5 to 6 g/day, follow-up 5 to 365 days; MetS-related parameters
Effect -1.509 mean difference, 95% CI -2.479 to -0.539
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.2024PMID:38755142Permalink
taurine — decreases fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Quoted verbatim from Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Pooled 25 RCTs (1024 participants) of taurine supplementation, 0.5 to 6 g/day, follow-up 5 to 365 days; MetS-related parameters
Effect -5.882 mean difference, 95% CI -10.747 to -1.018
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.2024PMID:38755142Permalink
taurine — decreases triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Quoted verbatim from Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Pooled 25 RCTs (1024 participants) of taurine supplementation, 0.5 to 6 g/day, follow-up 5 to 365 days; MetS-related parameters
Effect -18.315 mean difference, 95% CI -25.628 to -11.002
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.2024PMID:38755142Permalink
taurine — decreases systolic blood pressure (setting unspecified)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Quoted verbatim from Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Pooled 25 RCTs (1024 participants) of taurine supplementation, 0.5 to 6 g/day, follow-up 5 to 365 days; MetS-related parameters
Effect -3.999 mean difference, 95% CI -7.293 to -0.706
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.2024PMID:38755142Permalink
What did not
1 finding
taurine — no detected effect on HDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Quoted verbatim from Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Pooled 25 RCTs (1024 participants) of taurine supplementation, 0.5 to 6 g/day, follow-up 5 to 365 days; MetS-related parameters
Effect 0.644 mean difference, 95% CI -0.244 to 1.532
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.2024PMID:38755142Permalink